Please assess the completion status of the following clinical trial:

Trial Title: A Study in Adults and Adolescents With Angelman Syndrome (STARS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Age 13- 49 years~2. Diagnosis of Angelman syndrome~3. Receiving a stable regimen of concomitant medications for at least 4 weeks prior to Baseline, and able to maintain these throughout the duration of the study~4. Has a caregiver capable of providing informed consent on behalf of the subject and able to attend scheduled study visits~5. Able to ingest study medication~6. Caregivers must agree not to post any subject or study information on social media~Exclusion Criteria~1. Unable to perform the study related safety and exploratory efficacy assessments, such as motor function~2. Poorly controlled seizure activity~3. Concomitant cardiovascular, respiratory, liver, renal, or hematologic diseases of a degree that would limit participation in the study~4. Pregnancy or women of child-bearing potential who are not using and acceptable method of contraception~5. Concomitant use of minocycline, levodopa, zolpidem, zaleplon, eszopiclone, ramelteon, and cannabinoid derivatives, or any other use of any investigational agent, device, and/or investigational procedure 4 weeks prior to Baseline and during the study~6. Allergy to OV101 or any excipients~7. At increased risk of harming self and/or others based on investigator assessment~8. Any condition or reason that in the opinion of the investigator makes the subject unsuitable for enrollment~9. Inability of subject or caregiver to comply with study requirements~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- OV101 regimen 1 (Type: EXPERIMENTAL): OV101 once daily
- OV101 regimen 2 (Type: EXPERIMENTAL): OV101 twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).